Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Rad Source Technologies is a global leader in non-isotope X-ray irradiation technology, providing safe and effective alternatives to self-shielded gamma irradiators. The company specializes in developing advanced X-ray systems for blood irradiation to prevent Transfusion-Associated Graft-Versus-Host Disease (TA-GVHD), as well as for life science research involving small animals and cell cultures. Their proprietary Quastar technology offers high-dose uniformity and reliability across various applications, including immunology, oncology research, and cannabis decontamination. Headquartered in Georgia, Rad Source serves major hospitals, universities, and pharmaceutical companies worldwide, significantly reducing the regulatory and security burdens associated with radioactive materials.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Rad Source Technologies.